Long non-coding RNA RMRP promotes human glioma tumor progression via miR-466/CXCR4 pathway

Jie Zhang,Ling He,Xun Xia,Lie Zhang,Enren Wang

DOI: https://doi.org/10.21203/rs.3.rs-315866/v1

2021-03-17

Abstract:Abstract Purpose: Long non-coding RNA (lncRNA) RMRP has been confirmed to be associated with multiple tumor progression. However, the molecular regulatory mechanism of RMRP in human glioma was rarely elucidated. Methods: The quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression levels of RMRP, microRNA-466 (miR-466) and CXCR4 in glioma tissues and cells. The ELISA-BrdU assay and flow cytometry analysis was used to perform the cell proliferation, apoptotic rate, cell cycle assay in human glioma cell lines A172 and U251 cells. The starBase v2.0 or TargetScan was used to predict the potential interactions among RMRP, miR-466 and CXCR4, and the luciferase reporter assay was performed to validate the relationship among these molecules. The western blot was used to determine the expression levels of protein associated with cell cycle and CXCR4. Results: The levels of RMRP, CXCR4 were highly expressed, but miR-466 was decreased in glioma tissues and cells. And miR-466 was verified as a direct target of RMRP and directly regulated CXCR4. RMRP expression or miR-466 inhibitor promote cell proliferation and G1/S cell cycle transition but reduced apoptotic rate in A172 and U251 cells, while RMRP promote G1/S cell cycle transition through regulating CDK4 pathway, not CDK2 pathway. And that, the introduction of CXCR4 partly counteracted these impacts. In addition, RMRP silencing and miR-466 mimic impeded xenograft tumor growth in vivo . Conclusion: RMRP enhanced glioma progression, partially through miR-466/CXCR4 pathway. The molecular regulation mechanism based on RMRP/miR-466/CXCR4 might contribute to the diagnosis of glioma and provide the effective therapeutic targets for its treatment.